SCHEMBL26078529

SCHEMBL26078529

CC(C)Oc1cc(Cl)ccc1CC1=NCCN1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NISCH Q9Y2I1 4/20 0.51
▸ HTR1B P28222 6/20 0.47
▸ HTR1D P28221 5/20 0.47
▸ ADRA2C P18825 7/20 0.46
▸ ADRA2A P08913 6/20 0.46
▸ ADRA1A P35348 6/20 0.46
▸ ADRA2B P18089 5/20 0.46
▸ ADRA1D P25100 5/20 0.46
▸ ADRA1B P35368 5/20 0.46
▸ TAAR1 Q96RJ0 4/20 0.43
▸ LMNA P02545 1/20 0.40
▸ HTR1A P08908 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ OPRM1 P35372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26078550 0.87 ADRA2C (0.43) NISCHHTR1BHTR1DADRA2CADRA2A
SCHEMBL26078454 0.85 HTR1B (0.49) NISCHHTR1BHTR1DADRA2CADRA2A
SCHEMBL26078505 0.80 TAAR1 (0.56) NISCHHTR1BHTR1DADRA2CADRA2A
SCHEMBL26078506 0.80 ADRA2A (0.46) NISCHHTR1BHTR1DADRA2CADRA2A
SCHEMBL26078509 0.79 HTR1D (0.49) NISCHHTR1BHTR1DADRA2CADRA2A
SCHEMBL26078452 0.78 HTR1D (0.68) NISCHHTR1BHTR1DADRA2CADRA2A
SCHEMBL26078605 0.78 HTR1D (0.48) NISCHHTR1BHTR1DADRA2CADRA2A
SCHEMBL26078608 0.78 HTR1D (0.48) NISCHHTR1BHTR1DADRA2CADRA2A
SCHEMBL26078611 0.78 HTR1D (0.48) NISCHHTR1BHTR1DADRA2CADRA2A
SCHEMBL26078482 0.77 TAAR1 (0.56) NISCHHTR1BHTR1DADRA2CADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE CURASEN THERAPEUTICS, INC. 2023-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE ADRA1A, ADRB1, ADRA1D NISCH 1881/4885HTR1B 105/4885HTR1D 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback